Immunogenicity and safety of a low-dose diphtheria, tetanus and acellular pertussis combination vaccine with either inactivated or oral polio vaccine as a pre-school booster in UK children

Collins, C; Salt, P; McCarthy, Noel D.; Chantler, Tracey; Lane, Laura A.; Hemme, Fabienne; Diggle, Linda; Buttery, Jim; Kitchin, Nicholas; Moxon, E. Richard; Pollard, Andrew J.

doi:10.1016/j.vaccine.2004.04.027

Cited by 47 publications

(47 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Indeed, booster doses of pertussis vaccine were included for preschool children in 2004 in the UK because of outbreaks in primary school-aged children. 17 In some countries doses are also given at 1 year of age and there is increasing use of pertussis vaccine as part of the teenage booster to maintain higher levels of population immunity against the disease.…”

Section: Spacing and Making Space In Immunisation Schedulesmentioning

confidence: 99%

Childhood immunisation: what is the future?

Pollard

2007

Archives of Disease in Childhood

View full text Add to dashboard Cite

Section: Spacing and Making Space In Immunisation Schedulesmentioning

confidence: 99%

Childhood immunisation: what is the future?

Pollard

2007

Archives of Disease in Childhood

View full text Add to dashboard Cite

“…The combined reduced-antigen-content diphtheria, tetanus and acellular pertussis vaccine offers the opportunity to boost older children against recommended antigens, with the potential benefit of reduced reactogenicity compared to full-antigen content vaccines. [17][18][19][20][21][22][23][24] Protection against poliomyelitis has been afforded through administration of live attenuated OPV and IPV. IPV is increasingly preferred over OPV for the fact that it cannot, by its nature, induce vaccine associated paralytic poliomyelitis and that it can be combined with other injectable vaccines into a single vaccine formulation.…”

Section: Discussionmentioning

confidence: 99%

Booster vaccination at 6-8 years of age with a reduced antigen content dTpa-IPV vaccine is immunogenic and safe after priming with whole-cell pertussis vaccine

et al. 2008

View full text Add to dashboard Cite

Pertussis vaccines containing reduced amounts of antigen have been considered primarily for use in adolescents and adults to date. We evaluated a reduced antigen content combined diphtheria tetanus acellular pertussis and inactivated polio vaccine (dTpa-IPV) in 6-8 year-old children in Taiwan, who had received four doses of DTPw (combined diphtheria, tetanus, whole cell pertussis vaccine) and OPV (oral polio vaccine). One month after the booster dose, seroprotection rates and vaccine response rates to all antigens were at least 98.8%, and significant increases in antibody concentrations were observed. Booster vaccination was associated with minor local reactions and systemic symptoms. Symptoms of severe intensity did not occur, with the exception of local pain. The dTpa-IPV vaccine was immunogenic and well tolerated in 6-8 year-old children and offers an alternative to the current use of tetanus and diphtheria vaccine and OPV in Taiwan, addressing the established need for repeated booster vaccinations against pertussis at the same time.

show abstract

“…In a previous study conducted by the Oxford Vaccine Group, 300 preschool children who had received routine infant immunizations had 4 blood samples taken over 6 years between 2001 and 2007 (10). At the time of taking informed consent for this study, permission was obtained to store the remaining serum for use in further vaccine-related research.…”

Section: Methodsmentioning

confidence: 99%

Maintenance of Immune Response throughout Childhood following Serogroup C Meningococcal Conjugate Vaccination in Early Childhood

Khatami

Peters

Robinson

et al. 2011

Clin Vaccine Immunol

View full text Add to dashboard Cite

The objectives of this study were to evaluate the kinetics of antibody decline through childhood in a longitudinal study of a single cohort following serogroup C meningococcal (MenC) vaccine immunization in early childhood and to calculate the proportion of 11 to 13 year olds with protective levels of bactericidal antibody 10 years after immunization. United Kingdom children aged 11 to 13 years in 2010 who had previously taken part in a longitudinal study at the Oxford Vaccine Group had blood samples drawn between 2001 and 2010. Sera from each time point were analyzed for the MenC serum bactericidal antibody titer using a baby rabbit complement (rSBA) assay. The median age at MenC immunization was 21 months (range, 1 year 3 months to 3 years 9 months). The MenC rSBA geometric mean titer (GMT) at age 3.5 to 5 years was 8.0 (95% confidence interval, 6.5 to 9.9; n ‫؍‬ 287). By age 11.5 to 13.5 years, the rSBA GMT had declined to 3.3 (2.5 to 4.4; n ‫؍‬ 98). The percentage of children with rSBA titers of >1:8 (the threshold for protection) also declined from 38% (35% to 41%) to 15% (12% to 19%). We concluded that MenC rSBA titers wane rapidly following vaccination in early childhood and continue to decline into the second decade of life. Since nasopharyngeal colonization in adolescents probably provides the major reservoir for MenC in the population, declining immunity in this cohort is of concern. Sustaining high levels of antibody through booster vaccination in this cohort is likely necessary to avoid a resurgence of disease in the decade ahead.

show abstract

Immunogenicity and safety of a low-dose diphtheria, tetanus and acellular pertussis combination vaccine with either inactivated or oral polio vaccine as a pre-school booster in UK children

Cited by 47 publications

References 9 publications

Childhood immunisation: what is the future?

Childhood immunisation: what is the future?

Booster vaccination at 6-8 years of age with a reduced antigen content dTpa-IPV vaccine is immunogenic and safe after priming with whole-cell pertussis vaccine

Maintenance of Immune Response throughout Childhood following Serogroup C Meningococcal Conjugate Vaccination in Early Childhood

Contact Info

Product

Resources

About